Talk:Favipiravir: Difference between revisions
Content deleted Content added
also a chemical |
assessed for WP:MED |
||
Line 1: | Line 1: | ||
{{talk header}} |
{{talk header}} |
||
{{WikiProject Medicine}} |
{{WikiProject Medicine|class=Start|importance=Low}} |
||
{{reliable sources for medical articles|synonym1=T-705|synonym2=Avigan}} |
{{reliable sources for medical articles|synonym1=T-705|synonym2=Avigan}} |
Revision as of 07:36, 27 October 2015
This is the talk page for discussing improvements to the Favipiravir article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1 |
Medicine Start‑class Low‑importance | ||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Favipiravir.
|
Pharmacology Stub‑class Mid‑importance | ||||||||||
|
Chemicals Stub‑class Low‑importance | ||||||||||
|
interesting article
I find this a very interesting Arrrrticle. I especially like the quote from Professor Shiraki, "earlier administration of favipiravir is crucial to protect the life of an Ebola infected patient; it determines the survival rate."
Also, freedom is good.